We are live on ! Find out more
NSRX

Nasus Pharma
NSRX

2 hedge funds and large institutions have $21.6K invested in Nasus Pharma in 2025 Q3 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
2
Holders Change
+2
Holders Change %
–
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$16.1K
2
UBS Group
UBS Group
Switzerland
+$9.99K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
1
Morgan Stanley
New York
$13.3K +$16.1K +2,000 New
UBS Group
2
UBS Group
Switzerland
$8.25K +$9.99K +1,241 New

NSRX Hedge Fund Activity: Q3 2025 in Review

2 of the 7,622 institutional investors tracked by Wall St. Rank reported a position in Nasus Pharma (NSRX) for Q3 2025, worth a combined $21.6K.

Buyers outnumbered sellers: 2 funds opened new NSRX positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Morgan Stanley, opening a new position worth an estimated $16.1K.

  • 2 institutional investors held Nasus Pharma (NSRX) as of Q3 2025, up from 0 in Q2 2025.
  • Funds reported $21.6K of Nasus Pharma stock for Q3 2025.
  • 2 funds opened new Nasus Pharma positions in Q3 2025 and 0 closed out, a net change of +2 holders.
  • The largest Nasus Pharma buyer in Q3 2025 was Morgan Stanley, an estimated $16.1K added.

Based on aggregated 13F filings for Q3 2025.